Onco-Innovations Advances Optimization and Scale-Up of PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Ph 1 Clinical Studies November 24, 2025
Leukogene Therapeutics Receives Strategic Funding from SCRA to Accelerate Development of Cancer Immunotherapy Pipeline November 18, 2025
Update provided on Ph 1/2a AERIAL trial of LEU011 in patients with R/R solid tumours November 18, 2025
NEOK Bio Launches with $75 Million Series A funding to Advance Next-Gen Bispecific ADC in Oncology November 10, 2025
Merck Enters Research & Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT) November 10, 2025
IntoCell and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies November 10, 2025
Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies November 10, 2025
Dispatch Bio Announces Clinical Supply and Collaboration Agreement with BMS in Solid Tumors November 10, 2025
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors November 10, 2025
Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers published in eBioMedicine November 4, 2025
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development November 4, 2025
Myrio Therapeutics, University of Pennsylvania, and NYU Langone Health to develop next gen solid tumor T cell immunotherapeutics November 4, 2025
Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers November 4, 2025
SIOP 2025: Latest data of zurletrectinib (ICP-723) for the treatment of pediatric and adolescent patients with advanced solid tumors announced November 4, 2025
Updated Rezatapopt Monotherapy Interim Data Announced From PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation October 29, 2025
Takeda enters a license and collaboration agreement with Innovent Biologics for IBI363 and IBI343 October 29, 2025
FDA grants non-transferrable voucher for daraxonrasib (RMC-6236) under the Commissioner’s National Priority Voucher (CNPV) pilot program October 29, 2025